Original Investigation

Publication Year

First Author

# of weeks to first follow-up encounter, at least 3 months (at 12 weeks) since onset of semaglutide dose

Starting dose semaglutide

HbA1c % reduction at first follow-up encounter

HbA1c % reduction at second follow-up encounter (if applicable)

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2022

Garvey

20

2.4 mg

0.53%

0.55%

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.

2022

Ghusn

n/a

n/a

n/a

n/a

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

The STEP 3 Randomized Clinical Trial

2021

Wadden

n/a

n/a

n/a

n/a

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

2017

Ahren

56

1.0 mg

1.60%

n/a

Average percent reduction rate of HbA1c

1.07%